Intech Biopharm Corporation (TPEX:6461)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
21.85
-0.05 (-0.23%)
Feb 11, 2026, 1:30 PM CST

Intech Biopharm Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
113.8539.7825.8523.6538.921.11
Revenue Growth (YoY)
234.15%53.90%9.30%-39.21%84.30%26.50%
Cost of Revenue
217.42197.4189.84170.91158.27160
Gross Profit
-103.57-157.63-164-147.26-119.37-138.89
Selling, General & Admin
60.1755.4451.9952.1447.9839.35
Research & Development
184.82143.06104.49118.68126.6362.32
Operating Expenses
244.99198.5156.47170.82174.61101.67
Operating Income
-348.56-356.13-320.47-318.08-293.98-240.56
Interest Expense
-34.88-34.16-33.59-23.04-19.54-16.81
Interest & Investment Income
3.865.734.421.930.850.72
Currency Exchange Gain (Loss)
-0.410.030.040.18-0.080.02
Other Non Operating Income (Expenses)
16.4516.3111.6111.14116.26
EBT Excluding Unusual Items
-363.55-368.21-337.99-327.88-301.76-250.37
Pretax Income
-363.55-368.21-337.99-327.88-301.76-250.37
Income Tax Expense
6.8-----
Net Income
-370.35-368.21-337.99-327.88-301.76-250.37
Net Income to Common
-370.35-368.21-337.99-327.88-301.76-250.37
Shares Outstanding (Basic)
145137120116102100
Shares Outstanding (Diluted)
145137120116102100
Shares Change (YoY)
6.76%13.97%3.73%14.15%1.47%22.88%
EPS (Basic)
-2.55-2.68-2.81-2.82-2.97-2.50
EPS (Diluted)
-2.55-2.68-2.81-2.82-2.97-2.50
Free Cash Flow
-418.44-312.84-234.17-201.13-221.91-215.54
Free Cash Flow Per Share
-2.88-2.28-1.94-1.73-2.18-2.15
Gross Margin
-90.97%-----
Operating Margin
-306.15%-895.26%-1239.87%-1345.12%-755.76%-1139.79%
Profit Margin
-325.29%-925.63%-1307.64%-1386.55%-775.74%-1186.25%
Free Cash Flow Margin
-367.53%-786.44%-905.98%-850.56%-570.48%-1021.21%
EBITDA
-259.51-269.8-235.74-232.8-208.82-156.68
D&A For EBITDA
89.0586.3384.7385.2885.1683.88
EBIT
-348.56-356.13-320.47-318.08-293.98-240.56
Source: S&P Global Market Intelligence. Standard template. Financial Sources.